Seeking Alpha

dbwonder

dbwonder
Send Message
View as an RSS Feed
View dbwonder's Comments BY TICKER:
Latest  |  Highest rated
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    Based on the stock movements in the last few trading days, the volatility generate by this article is fading and GALE is rising. Lessons learned: do your own due diligence and form your own conclusion before investing in biotech start-up's.
    Feb 10 01:53 PM | 2 Likes Like |Link to Comment
  • CytRx's Aldoxorubicin's Potential Is Underestimated, Creating A Buying Opportunity [View article]
    Should lifetime cumulative dose be measured in m3 instead of m2?
    Feb 7 05:38 PM | Likes Like |Link to Comment
  • Galena Biopharma: Numerous Red Flags Suggest A Significant Overvaluation [View article]
    What with the DOW down >300 points and Nasdaq down >100 points AND the bashing from this article GALE is still staying above 50d sma. This stock is still overpriced, I am long though, just waiting for it to move lower and buy more. I believe in the science of this company.
    Feb 3 03:44 PM | 1 Like Like |Link to Comment
  • Ohr Pharmaceutical: Eye Drop Treatment For Wet AMD Could Sideline Eylea Momentum [View article]
    Phase II is definitely too far out into the future to put money in NOW. May be watch for a dip of 20% and go in then. I still don't buy the idea of an eye drop for AMD until further proof.
    Jul 19 01:18 PM | Likes Like |Link to Comment
  • Trius Therapeutics: The Next Big Small-Cap Biotech Mover? [View article]
    I found your article provided very helpful for potential investors. However I like to suggest pricing comparison would be more accurate if cost per course of treatment is used. Thanks!
    Jun 7 10:19 AM | Likes Like |Link to Comment
  • Trius Therapeutics: The Next Big Small-Cap Biotech Mover? [View article]
    Fascinating article, and your pricing estimate on tedizolid is actually on the conservative side. BTW, comparison pricing would be more accurate if measured per course of treatment rather than price per pill.
    Jun 6 09:55 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    Read this and get out of AMPE NOW!
    http://bit.ly/198445H
    May 30 07:17 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    Instead of betting on Ampion, I would rather put my money on TSRX, it has a molecule that is proven to be superior over existing molecules, it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) on an application related to its tedizolid phosphate molecules. TSRX is also a rumoured take over target by Cubist Pharmaceuticals because tedizolid in combination with daptomycin (made by Cubist) was shown to be superior to all other molecules tested against MRSA. (methicillin resistant staph aureas) I don't mean to crash the Ampio party, just trying to put things in proper perspective!
    May 24 03:33 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    I need to point out that sildenafil was never approved for use as an anti-hypertensive. It was during the research phase that it was discovered that it caused erection in test subjects. Therefore it was a new molecule, whereas danazol had been in the market for years. Even if danazol is proven to be effective against DME, it will have very limited upside potential. Many new uses were discovered for ASA as well, but hundreds of companies are making it. My point is: if danazol is already on the market, and if it is proven to be effective,what is stopping DME patients from buying it cheap on the internet and adjust the dose using a pill cutter?
    May 24 02:15 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    I also doubt all the ophthalmologists are going to give up the lucrative business of prescribing and charging for the procedures of applying Lucentis and Eyelea and instead tell their patients to go buy danazol at the corner pharmacy. That's not sound economics for the medical professionals!
    May 24 02:15 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    Danazol is indicated for treatment of endometriosis, its use is limited by its masculinizing side-effects.[2] Its role as a treatment for endometriosis has been largely replaced by the GnRH agonists because of serious side effects. I just cannot see any upside potential in remarketing an old drug for new use.
    May 23 03:19 PM | Likes Like |Link to Comment
  • Regeneron Shareholders Watching Optina Trial Closely [View article]
    Interesting article, if danazol is proven to be effective against DME, it will affect GENR negatively, but as for upside poytential for AMPE I have serious doubt since this is a repurposed drug
    May 23 01:13 PM | Likes Like |Link to Comment
COMMENTS STATS
12 Comments
3 Likes